The correlation of p22^phox and chemosensitivity in EGFR-TKI resistant lung adenocarcinoma.

ABSTRACT:

Background

Enhancing the chemosensitivity in the patients with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) resistant lung adenocarcinoma (LUAD) is pivotal in achieving their successful therapeutic outcome. We aimed to explore the mechanisms regarding the development of therapeutic resistance to chemotherapy in EGFR-TKI resistant LUAD. Methods: Microarray analysis lead to potential involvement of p22^phox, which was abundantly expressed in the cell lines harboring EGFR-TKI resistance and chemoresistance, and was known to regulate several important chemoresistance-associated factors such as hypoxia inducible factor-1? (HIF-1?) and epithelial-mesenchymal transition (EMT). We compared the status of p22^phox with that of chemoresistance, HIF-1? expression and EMT in LUAD cell lines. We immunolocalized p22^phox in the specimens of lung cancer patients.

Results

p22^phox and HIF-1? mRNAs were significantly elevated in the cells harboring EMT and chemoresistance. p22^phox knockdown enhanced chemosensitivity and reduced the expression of HIF-1? and EMT-associated factors. HIF-1? knockdown enhanced the chemosensitivity, while HIF-1? transfection induced EMT and chemoresistance in these cell lines. All LUAD patients with T790M mutation were associated with abundant p22^phox immunoreactivity in carcinoma cells.

Conclusions

The analysis of p22^phox in lung carcinoma tissues could provide new insights into the selection of chemotherapy for the patients with EGFR-TKI resistant LUAD.

SUBMITTER: Kobayashi M 

PROVIDER: S-EPMC6383684 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature